-Steven Grant Researcher Activity Profile

Research Author Detailed Information 

Steven Grant Publication Rate By Year

Steven Grant has published 1 paper(s) in 2003, 1 paper(s) in 2005, 3 paper(s) in 2006, 16 paper(s) in 2007, 7 paper(s) in 2008, for a total of 28 research publications in total.

Steven S Grant Author Information

LAST NAME: grant

FIRST NAME: steven

INITIALS: S

AFFILIATION:

Papers

Steven Grant's Publication Record

1. Targeting multiple arms of the apoptotic regulatory machinery. Year Published: 2007
Department of Medicine, Virginia Commonwealth University and Massey Cancer Center, Richmond, Virginia, USA.
2. An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells. Year Published: 2003
Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University, Medical College of Virginia, Richmond, Virginia 23298, USA.
3. Histone deacetylase inhibitors: insights into mechanisms of lethality. Year Published: 2005
Department of Medicine, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA 23298, USA.
4. Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells. Year Published: 2006
Division of Hematology/Oncology, Virginia Commonwealth University/Medical College of Virginia, MCV Station Box 230, Richmond VA 23298, USA.
5. Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment. Year Published: 2006
Department of Biochemistry, 401 College St., Massey Cancer Center, Room 2-108, Box 980035, Virginia Commonwealth University, Richmond VA 23298-0035, USA.
6. MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo. Year Published: 2006
Department of Biochemistry, Virginia Commonwealth University, Richmond, Virginia 23298, USA.
7. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Year Published: 2007
Department of Medicine, Virginia Commonwealth University and Massey Cancer Center, Richmond, Virginia 23298, USA.
8. Radiation-induced cell signaling: inside-out and outside-in. Year Published: 2007
Department of Biochemistry, Virginia Commonwealth University, 401 College Street, Box 980035, Richmond, VA 23298, USA.
9. Conjugated bile acids regulate hepatocyte glycogen synthase activity in vitro and in vivo via Galphai signaling. Year Published: 2007
Department of Biochemistry, Box 980035, Virginia Commonwealth University, Richmond VA 23298-0035, USA.
10. Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias. Year Published: 2007
Department of Biochemistry, Virginia Commonwealth University, Richmond, VA 23298, USA. stgrant@hsc.vcu.edu
11. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Year Published: 2007
Department of Medicine, Division of Hematology/Oncology, MCV Station Box 230, Virginia Commonwealth University, Richmond, VA 23298, USA.
12. Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. Year Published: 2007
Department of Biochemistry, Virginia Commonwealth University, Richmond, VA 23298-0035, USA.
13. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Year Published: 2007
Department of Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia 23298, USA.
14. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Year Published: 2007
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA.
15. RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. Year Published: 2007
16. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Year Published: 2007
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA. pbf1@columbia.edu
17. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Year Published: 2007
Department of Biochemistry, Box 980035, Virginia Commonwealth University, Richmond, VA 23298-0035. pdent@vcu.edu.
18. RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. Year Published: 2007
19. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Year Published: 2007
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA.
20. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Year Published: 2007
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA. pbf1@columbia.edu
21. Approaches for monitoring signal transduction changes in normal and cancer cells. Year Published: 2008
Department of Biochemistry, Virginia Commonwealth University, Richmond, USA.
22. Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells. Year Published: 2008
Authors' Affiliations: Departments of Medicine, Biochemistry, and Pharmacology, Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia.
23. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Year Published: 2007
Department of Biochemistry, Box 980035, Virginia Commonwealth University, Richmond, VA 23298-0035, USA.
24. Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Year Published: 2008
Department of Biochemistry, Virginia Commonwealth University, 401 College Street, Massey Cancer Center, Box 980035, Richmond, VA 23298-0035. pdent@vcu.edu.
25. Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling. Year Published: 2008
Department of Biochemistry, Virginia Commonwealth University, 401 College Street, Massey Cancer Center, Box 980035, Richmond, VA 23298-0035. pdent@vcu.edu.
26. PERK-dependent regulation of HSP70 expression and the regulation of autophagy. Year Published: 2008
Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia, USA.
27. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Year Published: 2008
Department of Medicine, Virginia Commonwealth University/Massey Cancer Center, Richmond, VA 23298, USA.
28. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Year Published: 2008
Department of Biochemistry, 401 College Street, Massey Cancer Center, Room 280a, Box 980035, Virginia Commonwealth University, Richmond, VA 23298-0035, USA.